IL-15 Protein (AA 49-162)

Catalog No. ABIN6386427

Product Details

Target: IL-15 (IL15) (Interleukin 15 (IL15))

Protein Type: Recombinant

Biological Activity: Active

Protein Characteristics: AA 49-162

Origin: Human

Source: Escherichia coli (E. coli)

Sequence: AA 49-162

Purity: >95 % as determined by SDS-PAGE.

Endotoxin Level: Less than 0.1 EU per μg by the LAL method.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: PBS, pH 7.4

Handling Advice: Please avoid repeated freeze-thaw cycles.

Storage: -20 °C

Target Details

Target: IL-15 (IL15) (Interleukin 15 (IL15))

Alternative Name: IL-15 (IL15 Products)

Synonyms: IL15 Protein, AI503618 Protein, IL-15 Protein, interleukin 15 Protein, IL15 Protein, Il15 Protein

Background: Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells, cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.

Molecular Weight: 12.8 kDa

Pathways: JAK-STAT Signaling, Glycosaminoglycan Metabolic Process